source
- Lilly's amylin-Zepbound combo shows 23% weight loss in type 2 diabetes patientsEli Lilly reported that its amylin‑Zepbound combination, eloraTZP, produced an average 23.3% weight loss in adults with type 2 diabetes who were also obese or overweight. The result was derived fro…
- Eli Lilly's retatrutide shows over a third of patients lose 25%+ weight in phase 3 trialEli Lilly presented detailed results from its phase 3 retatrutide trial at the European Association for the Study of Diabetes meeting in Milan and in a recent Lancet publication. The study enrolle…